Pyxis Oncology (PYXS) Stock Price, News & Analysis

Company Overview

Pyxis Oncology, Inc. (NASDAQ: PYXS) is a clinical-stage biotechnology company developing therapies for cancer. The company focuses on treatments designed to address both tumor cells and the tumor microenvironment, with the goal of improving the effectiveness of the immune system and other anticancer mechanisms against solid tumors.

Its research and development programs include antibody-drug conjugates and immunotherapies. Pyxis Oncology’s lead program, PYX-201, is an antibody-drug conjugate designed to target the extradomain B form of fibronectin, a protein found in the tumor microenvironment, and deliver an anticancer payload to tumor tissue. The company has also developed additional antibody-based programs intended to modulate immune responses or target features associated with cancer.

Pyxis Oncology was founded in 2019 and is headquartered in Boston, Massachusetts. Its therapies are in clinical development, and the company’s programs are being evaluated in cancer indications with significant unmet medical needs. Lara Sullivan, M.D., is a co-founder and has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $1.98 to $2.06
• 50-Day Range: $1.99 to $3.89
• 52-Week Range: $1.03 to $5.55
• Volume: 950,365 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $169.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.75
• Consensus Rating: Moderate Buy

Pyxis Oncology Stock Analysis - MarketRank™

Pyxis Oncology scored higher than 52% of companies evaluated by MarketBeat, and ranked 472nd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Pyxis Oncology has a consensus price target of $8.75, representing about 331.0% upside from its current price of $2.03.

Amount of Analyst Coverage

Pyxis Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pyxis Oncology are expected to grow in the coming year, from ($1.21) to ($1.10) per share.

Price to Book Value per Share Ratio

Pyxis Oncology has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.21% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 4.05.

Change versus previous month

Short interest in Pyxis Oncology has recently increased by 4.45%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pyxis Oncology does not currently pay a dividend.

Dividend Growth

Pyxis Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.95

News Sentiment

Pyxis Oncology has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Pyxis Oncology this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of Pyxis Oncology is held by insiders.

Percentage Held by Institutions

39.07% of the stock of Pyxis Oncology is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PYXS
• CIK: 1782223
• Web: www.pyxisoncology.com
• Phone: 617-221-9059
• Fax: N/A
• Employees: 56
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Pyxis Oncology: $8.75
• High Price Target: $19.00
• Low Price Target: $5.00
• Potential Upside/Downside: +331.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.62 million
• Net Margins: N/A
• Pretax Margin: -793.84%
• Return on Equity: -215.23%
• Return on Assets: -112.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $13.86 million
• Price / Sales: 12.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.86 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 83,410,000
• Free Float: 78,654,000
• Market Cap: $169.32 million
• Optionable: Optionable
• Beta: 1.37